Drug intelligence / Profile preview

Radiocaine

Development stage
Unknown
Lead developer
Lutroo Imaging
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration
Intravenous
01

Overview

Radiocaine is a first-in-class PET radiotracer developed by Lutroo Imaging for the visualization and quantification of pain. It consists of a fluorine-18-labeled small molecule designed to bind specifically to voltage-gated sodium channels, which are upregulated in peripheral nerves during various painful conditions, including neuropathic, inflammatory, and cancer-related pain. By targeting these channels, Radiocaine serves as an imaging biomarker to localize pain sources, such as in lower back pain and neuropathic pain disorders. It received FDA Fast Track Designation in July 2025 and is currently undergoing Phase 1 clinical evaluation for safety, biodistribution, and radiation dosimetry.

Brand names
Radiocaine
Other names
Fluorine-18-labeled radiocaineFluorine18-labeled radiocaineFluorine 18-labeled radiocaine
02

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on Radiocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Radiocaine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call